Go Back   HER2 Support Group Forums > her2group
Register Gallery FAQ Members List Calendar Search Today's Posts Mark Forums Read

Thread Tools Display Modes
Old 06-18-2020, 12:47 PM   #1
Senior Member
Join Date: Mar 2006
Posts: 4,772
Thumbs up Tucatinib Is Active Against Brain Metastases in HER2+ Breast Cancer

Research Watch
Tucatinib Is Active Against Brain Metastases in HER2+ Breast Cancer

DOI: 10.1158/2159-8290.CD-RW2020-087

  • Major Finding: The small-molecule tyrosine kinase inhibitor tucatinib outperformed placebo against brain metastases.
  • Concept: Adding tucatinib to trastuzumab plus capecitabine extended overall survival by more than six months.
  • Impact: Although exploratory, this work shows the promise of tucatinib for brain-metastatic HER2+ disease.

Brain metastases, which arise in half of patients with metastatic HER2-positive breast cancer, are difficult to treat and a major cause of mortality. Lin and colleagues conducted exploratory analyses on a subset of data from the randomized, controlled, double-blinded HER2CLIMB trial, specifically focusing their investigation on the utility of the small-molecule oral tyrosine kinase inhibitor tucatinib in patients with brain-metastatic HER2-positive breast cancer. Among the 612 patients enrolled in the HER2CLIMB trial, 291 (48%) had brain metastases or a history of brain metastases; these 291 patients were the subject of this work. Most of these patients (87.3%) had undergone prior treatment for their brain metastases, including surgery and/or whole-brain or targeted radiation therapy. With regard to overall survival (OS), the results in the tucatinib arm (tucatinib plus the HER2 antibody trastuzumab and the cytotoxic chemotherapy drug capecitabine) were superior to those in the control arm (placebo plus trastuzumab and capecitabine), with median OS values of 18.1 months in the tucatinib group and 12.0 months in the control group. Importantly, the survival benefit of tucatinib was mostly seen in the 174 patients with active brain metastases, in whom the median OS was 20.7 months with tucatinib versus 11.6 months with placebo; in the 117 patients with stable brain metastases, the median OS was 15.7 months with tucatinib versus 13.6 months with placebo. However, tucatinib showed signs of central nervous system (CNS) activity in both groups, with CNS progression-free survival being 9.9 months with tucatinib versus 4.2 months with placebo among all patients, 9.5 months versus 4.1 months among patients with active brain metastases, and 13.9 months versus 5.6 months in patients with stable brain metastases. Although limited by its exploratory nature, this analysis supports the notion that tucatinib is an agent of interest in specifically treating brain metastases in patients with HER2-positive breast cancer, a topic worth investigating prospectively in future trials.
Lin NU, Borges V, Anders C, Murthy RK, Paplomata E, Hamilton E, et al. Intracranial efficacy and survival with tucatinib plus trastuzumab and capecitabine for previously treated HER2-positive breast cancer with brain metastases in the HER2CLIMB trial. Jour Clin Oncol 2020 May 29 [Epub ahead of print].

Note: Research Watch is written by Cancer Discovery editorial staff. Readers are encouraged to consult the original articles for full details. For more Research Watch, visit Cancer Discovery online

Lani is offline   Reply With Quote
Old 06-18-2020, 02:58 PM   #2
Senior Member
Join Date: Oct 2013
Posts: 423
Re: Tucatinib Is Active Against Brain Metastases in HER2+ Breast Cancer

One thing about Tucatanib surprised me when I looked at the package insert. It can cause severe diarrhea. When it first was being researched they didn't think it would because it wasn't supposed to inhibit the epidermal growth factor receptor, just the Her 2 neu receptor. Still the fact that it is effective against brain mets is exciting news.

Other Tukasyn side effects are liver damage (possible) fatigue. hand foot syndrome, anorexia and stomatitis, vomiting and diarrhea The dose is 300mg every 12 hours.

donocco is offline   Reply With Quote
Old 06-25-2020, 12:20 PM   #3
Senior Member
Join Date: Oct 2013
Posts: 423
Re: Tucatinib Is Active Against Brain Metastases in HER2+ Breast Cancer

They don't use Tucatanib alone. It is combined with Xeloda 1000mg per square meter twice a day.

I learned a quick formula for determining Body Surface Area in pharmacy school long ago. Multiply your height in inches times your weight in pounds and divide this number by 3,131. Then take the square root of this number snd you have a pretty good approximation of your body surface area. Some might find this formula useful as many drugs are given in mg /square meter.

BSA= body weight in pounds X height in inches divided by 3131, and take the square root of the this final number.

Hope this comes in handy

donocco is offline   Reply With Quote

Thread Tools
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is Off

Forum Jump

All times are GMT -7. The time now is 03:17 PM.

Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2020, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007
free webpage hit counter